Historique
Périodique
Postmarketing surveillance of abuse liability of sibutramine
(Surveillance post-marketing du potentiel d'abus de la sibutramine)
Auteur(s) :
ARFKEN, C. L. ;
SCHUSTER, C. R. ;
JOHANSON, C. E.
Année :
2003
Page(s) :
169-173
Langue(s) :
Anglais
Refs biblio. :
13
Domaine :
Autres substances / Other substances
Discipline :
EPI (Epidémiologie / Epidemiology)
Note générale :
Drug and Alcohol Dependence, 2003, 69, (2), 169-173
Note de contenu :
tabl.
Résumé :
ENGLISH :
The abuse liability of medications is a growing concern as the number of newly approved psychoactive medications increases. Postmarketing surveillance can assist in determining abuse liability, but strategies are not well-defined for medications believed to be at low abuse risk. Using a newly approved medication (sibutramine-an anorectic drug), a novel approach to postmarketing abuse surveillance was introduced. A one-page anonymous questionnaire covering sibutramine, a scheduled anorectic drug (phentermine), and a fabricated name was added to the intake process of 58 treatment programs. From the 8780 completed questionnaires, 8.8% had heard of sibutramine and phentermine. For continued use to get high (a proxy for abuse), the rate for sibutramine was lower than for phentermine (0.6 vs. 2.2%, McNemar's c2 = 110.45, P
Affiliation :
Dept. Psychiatry Behav. Neurosci., Addic. Res. Inst., Wayne State Univ., 2761 E. Jefferson, Detroit, MI 48207
Etats-Unis. United States.
Etats-Unis. United States.